Genstar Capital acquired Oncure Medical Corp., an owner and operator of treatment centers for cancer patients, in August 2006 for an undisclosed amount, and we wouldn’t be surprised to see it go on the block soon.
The Englewood, Colo.-based company partners with radiation oncology medical groups to offer cancer patients a range of radiation treatment options. The company was founded in 1998 and today has treatment centers in Colorado, California, Florida and Indiana. It posted $103.3 million in revenue and $29.5 million in EBITDA for the year ended Dec. 31, 2011, according to Capital IQ. The company has total debt of $210.7 million and is leveraged at 7.2x its EBITDA, according to the same source.
At the time of its acquisition, the radiation therapy sector was a $7 billion market that was growing and highly fragmented, with lots of smaller companies that could be combined, according to trade magazine Mergers & Acquisitions. Early on, Genstar executives made it clear they intended to rapidly expand the company.
“OnCURE is now well-positioned as a platform investment and there are a number of strategic and organic expansion opportunities that we will pursue to further grow the business,” Jean-Pierre Conte, chairman of the firm, said at the time of the investment.
Under Genstar, the company has completed at least four add-on acquisitions of cancer treatment centers, all in 2007 and 2008, which helped expand the company’s geographic reach, according to Capital IQ.
The company has had some turnover in its CEO role under Genstar. Richard Zehner, who had founded Alliance Imaging Inc., a publicly traded company, was the CEO at the time Genstar bought the company. In June 2007, almost a year after the acquisition, the company appointed David Chernow, formerly a director for the company, as CEO. And in 2010, the company appointed Duane Choate, previously the company’s executive vice president and CFO, as president and CEO. The circumstances around the changes are unclear.
Genstar has raised about $900 million for its next fund, bringing it within reach of its $1 billion goal, according to Bloomberg.
Executives at Genstar declined to comment.